

BioCentury Week in Review

ESSENTIAL SURVEILLANCE FOR BIOTECH & PHARMA

Week in Review, Deals

Genenta Science, Amgen, Ospedale San Raffaele deal

Published on Monday, September 26, 2016

[Genenta Science s.r.l.](#), Milan, Italy

[Amgen Inc.](#) (NASDAQ:AMGN), Thousand Oaks, Calif.

[Ospedale San Raffaele](#), Milan, Italy

Business: Cancer

Genenta, San Raffaele and Amgen partnered to evaluate myeloid-targeted hematopoietic stem cell (HSC) therapies to treat cancer. The partners will use Genenta's HSC platform, which it licensed from San Raffaele. Genenta and Amgen declined to provide details.

All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the [BioCentury User Agreement](#) and the [BioCentury Terms of Use](#). The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from [Reprints/Permissions](#) at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.